Stability of esmolol hydrochloride and sodium nitroprusside in intravenous admixtures.
The stability of esmolol hydrochloride and sodium nitroprusside in an admixture containing both drugs was studied. Solutions containing sodium nitroprusside in a final concentration of approximately 200 micrograms/mL and esmolol hydrochloride in a final concentration of 10 mg/mL in 5% dextrose injection were prepared in a 250-mL volumetric flask. The flask was wrapped with a light-protective cover, stored at ambient room temperature (15-30 degrees C), and protected from light. All experiments were conducted in triplicate with samples taken at 0, 2, 4, 8, and 24 hours. Testing included measurement of pH and absorbance at 400 and 600 nm. High-performance liquid chromatography was used to measure esmolol hydrochloride and sodium nitroprusside concentrations. No changes were observed in the physical appearance, pH, or absorbance of the admixtures. Neither the esmolol hydrochloride nor the sodium nitroprusside concentrations varied by more than 4% during the study. Under the conditions studied, esmolol hydrochloride is compatible with sodium nitroprusside in an admixture containing both drugs.
Karnatz
N N
NN
Regulatory Affairs and Quality Assurance Department, Du Pont Critical Care, Waukegan, IL 60085.
Wong
J
J
Baaske
D M
DM
Johnson
J H
JH
Speicher
E R
ER
Herbranson
D E
DE
D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000032:analysis*; D005292:Ferricyanides / Q000032:analysis*; D007262:Infusions, Intravenous; D009599:Nitroprusside / Q000008:administration & dosage / Q000032:analysis*; D011412:Propanolamines / Q000008:administration & dosage / Q000032:analysis*; D013055:Spectrophotometry, Infrared
D000319:Adrenergic beta-Antagonists; D005292:Ferricyanides; D011412:Propanolamines; D009599:Nitroprusside; C036604:esmolol